DK0837860T3 - Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner - Google Patents

Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner

Info

Publication number
DK0837860T3
DK0837860T3 DK95918707T DK95918707T DK0837860T3 DK 0837860 T3 DK0837860 T3 DK 0837860T3 DK 95918707 T DK95918707 T DK 95918707T DK 95918707 T DK95918707 T DK 95918707T DK 0837860 T3 DK0837860 T3 DK 0837860T3
Authority
DK
Denmark
Prior art keywords
triazolo
pyrazolo
pyridines
tricyclic
dihydro
Prior art date
Application number
DK95918707T
Other languages
Danish (da)
English (en)
Inventor
Allen J Duplantier
Kelvin Cooper
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0837860T3 publication Critical patent/DK0837860T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK95918707T 1995-06-06 1995-06-06 Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner DK0837860T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002223624A CA2223624C (en) 1995-06-06 1995-06-06 Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
PCT/IB1995/000429 WO1996039408A1 (en) 1995-06-06 1995-06-06 TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-α]PYRIDINES
HU9601541A HUP9601541A3 (en) 1995-06-06 1996-06-05 Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolol[4,3-a]-pyridines and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
DK0837860T3 true DK0837860T3 (da) 2002-05-27

Family

ID=89994031

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95918707T DK0837860T3 (da) 1995-06-06 1995-06-06 Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner

Country Status (43)

Country Link
US (1) US6004974A (bg)
EP (1) EP0837860B1 (bg)
JP (1) JP3107827B2 (bg)
KR (2) KR100191972B1 (bg)
CN (1) CN1061044C (bg)
AP (1) AP609A (bg)
AR (1) AR002745A1 (bg)
AT (1) ATE214700T1 (bg)
AU (1) AU694871B2 (bg)
BG (1) BG62568B1 (bg)
BR (1) BR9602627A (bg)
CA (1) CA2223624C (bg)
CO (1) CO4700460A1 (bg)
CZ (1) CZ287251B6 (bg)
DE (1) DE69525978T2 (bg)
DK (1) DK0837860T3 (bg)
DZ (1) DZ2044A1 (bg)
ES (1) ES2172583T3 (bg)
FI (1) FI114097B (bg)
HR (1) HRP960268B1 (bg)
HU (1) HUP9601541A3 (bg)
IL (1) IL118485A (bg)
IS (1) IS1913B (bg)
LV (1) LV11620B (bg)
MA (1) MA23893A1 (bg)
MX (1) MX9709897A (bg)
MY (1) MY116527A (bg)
NO (1) NO306256B1 (bg)
NZ (1) NZ286734A (bg)
OA (1) OA10458A (bg)
PL (1) PL184195B1 (bg)
PT (1) PT837860E (bg)
RO (1) RO115881B1 (bg)
RU (1) RU2161158C2 (bg)
SA (1) SA96170065B1 (bg)
SG (1) SG54341A1 (bg)
SI (1) SI9600186A (bg)
SK (1) SK282167B6 (bg)
TN (1) TNSN96083A1 (bg)
TR (1) TR199600482A1 (bg)
TW (1) TW460469B (bg)
WO (1) WO1996039408A1 (bg)
YU (1) YU49346B (bg)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792938B1 (fr) 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
EP1380585B1 (en) * 1999-04-30 2004-11-10 Pfizer Products Inc. Pyrazolopyridinone as intermediate
US6326495B2 (en) * 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
WO2001068600A2 (en) * 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Limited Benzylated pde4 inhibitors
EP1397135B1 (en) * 2001-05-25 2006-12-06 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways
US20040147544A1 (en) * 2001-05-25 2004-07-29 Michael Yeadon Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
GB0122031D0 (en) * 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
GB0129395D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
WO2006075748A1 (ja) * 2005-01-17 2006-07-20 Santen Pharmaceutical Co., Ltd. アレルギー性結膜疾患治療剤
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN102764440A (zh) 2006-07-05 2012-11-07 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
CA2739148A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
ES2527363T3 (es) 2009-12-04 2015-01-22 Nerviano Medical Sciences S.R.L. Derivados de triciclopirazol
WO2013084182A1 (en) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697532A (en) * 1970-08-12 1972-10-10 Squibb & Sons Inc 5-methyldipyrazolo {8 3,4-b;3{40 ,4{40 -d{9 {0 pyridin-3(2h)-ones
NZ266525A (en) * 1993-07-06 1997-10-24 Pfizer 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine derivatives and medicaments
CA2143143A1 (en) * 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives

Also Published As

Publication number Publication date
NO306256B1 (no) 1999-10-11
US6004974A (en) 1999-12-21
MA23893A1 (fr) 1996-12-31
TW460469B (en) 2001-10-21
NZ286734A (en) 1998-02-26
TR199600482A1 (tr) 1997-03-21
CZ287251B6 (en) 2000-10-11
AR002745A1 (es) 1998-04-29
HU9601541D0 (en) 1996-07-29
CO4700460A1 (es) 1998-12-29
BR9602627A (pt) 1998-09-01
NO962320D0 (no) 1996-06-05
CZ162696A3 (en) 1997-01-15
MX9709897A (es) 1998-03-31
JPH10510242A (ja) 1998-10-06
TNSN96083A1 (fr) 2005-03-15
FI974434A (fi) 1997-12-05
HUP9601541A2 (en) 1997-02-28
EP0837860B1 (en) 2002-03-20
IS4350A (is) 1996-12-07
KR100191972B1 (ko) 1999-06-15
FI114097B (fi) 2004-08-13
LV11620B (en) 1997-04-20
CN1142499A (zh) 1997-02-12
SK71896A3 (en) 1997-05-07
IL118485A0 (en) 1996-09-12
MY116527A (en) 2004-02-28
DE69525978T2 (de) 2002-12-19
DZ2044A1 (fr) 2002-07-21
YU34696A (sh) 1999-07-28
LV11620A (lv) 1996-12-20
HUP9601541A3 (en) 1997-05-28
CA2223624A1 (en) 1996-12-12
CA2223624C (en) 2001-02-20
AU694871B2 (en) 1998-07-30
PL184195B1 (pl) 2002-09-30
RO115881B1 (ro) 2000-07-28
IL118485A (en) 2000-02-17
NO962320L (no) 1996-12-09
HRP960268A2 (en) 1997-08-31
ES2172583T3 (es) 2002-10-01
KR100225719B1 (en) 1999-10-15
EP0837860A1 (en) 1998-04-29
BG100640A (bg) 1997-03-31
AU5477396A (en) 1996-12-19
SK282167B6 (sk) 2001-11-06
CN1061044C (zh) 2001-01-24
FI974434A0 (fi) 1997-12-05
AP609A (en) 1997-09-03
OA10458A (en) 2002-03-27
SI9600186A (en) 1997-04-30
DE69525978D1 (de) 2002-04-25
WO1996039408A1 (en) 1996-12-12
RU2161158C2 (ru) 2000-12-27
HRP960268B1 (en) 2002-12-31
AP9600806A0 (en) 1996-07-31
YU49346B (sh) 2005-07-19
PL314459A1 (en) 1996-12-09
SG54341A1 (en) 1998-11-16
JP3107827B2 (ja) 2000-11-13
KR970003440A (ko) 1997-01-28
PT837860E (pt) 2002-07-31
SA96170065B1 (ar) 2005-12-21
BG62568B1 (bg) 2000-02-29
ATE214700T1 (de) 2002-04-15
IS1913B (is) 2004-02-03

Similar Documents

Publication Publication Date Title
DE59409351D1 (de) Pyrrolo[3,4-c]pyrrole
DE59903421D1 (de) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on
IL147752A0 (en) Imidazo[1,2-a] pyridine and pyrazolo [2,3-a] pyridine derivatives
DE69635922D1 (de) Tricyclische benzazepin vasopressinantagonisten
IS4570A (is) Imidazó[1,2-a]pýridín afleiður
NZ301198A (en) Tricyclic diazepine derivatives having oxytocin antagonist activity
DK0837860T3 (da) Tricykliske 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alfa]pyridiner
DE69529777T2 (de) 2-Benzylthio-8-amino(1,2,4)triazolo(1,5-a)pyridine
AU4025789A (en) Tricyclic benzodiazepine derivatives
HU9300488D0 (en) Tricyclic benzodiazepine derivatives
PL327539A1 (en) 2,7-substituted derivatives of octahydropyrrole[1,2-a]-pyrazine
HU9901909D0 (en) Spiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]
DE69014784T2 (de) Antivirale Tetrahydroimidazo[1,4]benzodiazepine.
ZA964649B (en) Tricyclic 5,6-dihydro-9H-pyrazolo[3,4c]-1,2,4-triazolo[4,3a]pyridines.
MX9700716A (es) 2-aril-5,11-dihidro-6h-dipirido[3,2-b:2',3'-e][1,4] diazepinas y su uso en el tratamiento de la infeccion por vih.